EP3383884A4 - Verfahren zur verhinderung oder behandlung von nosokomialer pneumonie - Google Patents
Verfahren zur verhinderung oder behandlung von nosokomialer pneumonie Download PDFInfo
- Publication number
- EP3383884A4 EP3383884A4 EP16871318.8A EP16871318A EP3383884A4 EP 3383884 A4 EP3383884 A4 EP 3383884A4 EP 16871318 A EP16871318 A EP 16871318A EP 3383884 A4 EP3383884 A4 EP 3383884A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preventing
- nosocomial pneumonia
- treating nosocomial
- treating
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260935P | 2015-11-30 | 2015-11-30 | |
PCT/US2016/063865 WO2017095744A1 (en) | 2015-11-30 | 2016-11-28 | Method for preventing or treating nosocomial pneumonia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3383884A1 EP3383884A1 (de) | 2018-10-10 |
EP3383884A4 true EP3383884A4 (de) | 2019-07-31 |
Family
ID=58798034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16871318.8A Withdrawn EP3383884A4 (de) | 2015-11-30 | 2016-11-28 | Verfahren zur verhinderung oder behandlung von nosokomialer pneumonie |
Country Status (11)
Country | Link |
---|---|
US (2) | US11066461B2 (de) |
EP (1) | EP3383884A4 (de) |
JP (2) | JP7110095B2 (de) |
KR (1) | KR20180088442A (de) |
CN (1) | CN108368149A (de) |
AU (1) | AU2016362202B2 (de) |
CA (1) | CA3005665A1 (de) |
HK (2) | HK1254854A1 (de) |
IL (1) | IL259509A (de) |
SG (2) | SG10201913100WA (de) |
WO (1) | WO2017095744A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2718320T (pt) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | Moléculas de ligação anti-psl de pseudomonas e suas utilizações |
JP6182152B2 (ja) * | 2011-11-07 | 2017-08-16 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
AU2016362202B2 (en) | 2015-11-30 | 2020-02-27 | Medimmune Limited | Method for preventing or treating nosocomial pneumonia |
CN113966343A (zh) * | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
WO2023281120A1 (en) | 2021-07-09 | 2023-01-12 | Luxembourg Institute Of Health (Lih) | Dimeric protein complexes and uses thereof |
WO2024003103A1 (en) * | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014074528A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP1690934A3 (de) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Bildung von xenogenen Antikörpern |
PT2718320T (pt) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | Moléculas de ligação anti-psl de pseudomonas e suas utilizações |
JP6182152B2 (ja) | 2011-11-07 | 2017-08-16 | メディミューン,エルエルシー | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
CA2911209A1 (en) | 2013-05-14 | 2014-11-20 | Medimmune, Llc | Synthetic oligosaccharide subunits of the psl exopolysaccharide of pseudomonas aeruginosa and uses thereof |
WO2015171504A1 (en) * | 2014-05-05 | 2015-11-12 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
AU2016362202B2 (en) | 2015-11-30 | 2020-02-27 | Medimmune Limited | Method for preventing or treating nosocomial pneumonia |
-
2016
- 2016-11-28 AU AU2016362202A patent/AU2016362202B2/en active Active
- 2016-11-28 SG SG10201913100WA patent/SG10201913100WA/en unknown
- 2016-11-28 US US15/779,189 patent/US11066461B2/en active Active
- 2016-11-28 WO PCT/US2016/063865 patent/WO2017095744A1/en active Application Filing
- 2016-11-28 EP EP16871318.8A patent/EP3383884A4/de not_active Withdrawn
- 2016-11-28 CA CA3005665A patent/CA3005665A1/en active Pending
- 2016-11-28 SG SG11201803794YA patent/SG11201803794YA/en unknown
- 2016-11-28 KR KR1020187018422A patent/KR20180088442A/ko unknown
- 2016-11-28 JP JP2018526715A patent/JP7110095B2/ja active Active
- 2016-11-28 CN CN201680068970.2A patent/CN108368149A/zh active Pending
-
2018
- 2018-05-22 IL IL259509A patent/IL259509A/en unknown
- 2018-11-01 HK HK18113950.1A patent/HK1254854A1/zh unknown
- 2018-12-18 HK HK18116170.8A patent/HK1257193A1/zh unknown
-
2021
- 2021-06-22 US US17/354,161 patent/US20220041695A1/en not_active Abandoned
-
2022
- 2022-07-20 JP JP2022115219A patent/JP2022163050A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014074528A2 (en) * | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
Also Published As
Publication number | Publication date |
---|---|
CN108368149A (zh) | 2018-08-03 |
IL259509A (en) | 2018-07-31 |
AU2016362202A1 (en) | 2018-07-05 |
HK1254854A1 (zh) | 2019-07-26 |
SG10201913100WA (en) | 2020-03-30 |
CA3005665A1 (en) | 2017-06-08 |
SG11201803794YA (en) | 2018-06-28 |
EP3383884A1 (de) | 2018-10-10 |
US11066461B2 (en) | 2021-07-20 |
JP2018535227A (ja) | 2018-11-29 |
AU2016362202A8 (en) | 2018-07-19 |
JP7110095B2 (ja) | 2022-08-01 |
KR20180088442A (ko) | 2018-08-03 |
US20180355026A1 (en) | 2018-12-13 |
JP2022163050A (ja) | 2022-10-25 |
US20220041695A1 (en) | 2022-02-10 |
HK1257193A1 (zh) | 2019-10-18 |
AU2016362202B2 (en) | 2020-02-27 |
WO2017095744A1 (en) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3500289A4 (de) | Verfahren zur behandlung von tracheobronchomalazie | |
EP3411548A4 (de) | Systeme und verfahren zur eingangskontrolle | |
EP3140798A4 (de) | System und verfahren zur tokendomänensteuerung | |
EP3229808A4 (de) | Verfahren zur behandlung von pilzinfektionen | |
EP3276578A4 (de) | Verfahren zur darstellung eines objekts | |
HK1257193A1 (zh) | 用於預防或治療醫源性肺炎的方法 | |
AU2016353600B2 (en) | Method for treating mucositis | |
EP3470078A4 (de) | Zusammensetzung unter verwendung eines schlitzrobotersystems zur vorbeugung oder behandlung von sarkopenie | |
EP3325624A4 (de) | Verfahren zur detektion und behandlung von infektionen mit niedriger virulenz | |
EP3334432A4 (de) | Cerdulatinib zur behandlung von myelom | |
EP3256117A4 (de) | Verfahren zur behandlung von neuroblastomen | |
EP3194025A4 (de) | Verfahren zur prävention oder behandlung von osteoarthritis | |
EP3345996A4 (de) | Verfahren zur herstellung von gamma-glutamyl-valyl-glycin | |
SG11201609647VA (en) | Coating method | |
EP3260526A4 (de) | Produktionssystem und produktionsverfahren für organische verbindungen oder mikroben | |
EP3553048A4 (de) | Verfahren zur herstellung von caprolactam | |
EP3381911A4 (de) | Verfahren zur herstellung von valerolacton | |
PL3322538T3 (pl) | Instalacja powlekająca i odpowiedni sposób eksploatacji | |
EP3163301A4 (de) | Verfahren zur diagnose, behandlung, oder prävention von stimmungsstörungen | |
EP3485993A4 (de) | Spinformungsverfahren | |
EP3348544A4 (de) | Verfahren zur herstellung von caprolactam | |
EP3554530C0 (de) | Antibakterielles verfahren | |
EP3246432A4 (de) | Verfahren zur behandlung von teilen | |
EP3239392A4 (de) | Verfahren zur beschichtung von polyketongarn | |
EP3157633A4 (de) | Verfahren zur behandlung von infektionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180702 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190701 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/04 20060101AFI20190625BHEP Ipc: C12P 21/08 20060101ALI20190625BHEP Ipc: C07K 16/00 20060101ALI20190625BHEP Ipc: A61K 39/00 20060101ALI20190625BHEP Ipc: A61K 39/104 20060101ALI20190625BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1257193 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261180 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200612 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230414 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230421 |